Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

99.06 +0.71 (+0.72%)
Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
26 27 Next >
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
New York Post 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Via Benzinga
Health Care Company Novartis Announces Merger With Chinook Therapeutics
Via Benzinga
Is Novartis a Good Stock to Buy Right Now?
The multinational pharma giant excels as an income play. 
Via The Motley Fool
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
7 Top Growth Stocks to Watch for H2 2023
Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023. 
Via InvestorPlace
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation
Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,  
Via Benzinga
Why Shares of Vera Therapeutics Jumped Tuesday
The company announced early phase 2 trials information regarding its lead therapy. 
Via The Motley Fool
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
  
Via Benzinga
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union. 
Via The Motley Fool
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that  
Via Benzinga
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
Stocks kept powering higher despite, but the Nasdaq is looking extended. 
Via Investor's Business Daily
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock. 
Via InvestorPlace
Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover
Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company. 
Via Investor's Business Daily
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
Find out more about two big winners Monday morning. 
Via The Motley Fool
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger 
Via Benzinga
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS). 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
Why Are Chinook Therapeutics Shares Trading Higher Today
Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,  
Via Benzinga
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories
Wall Street Journal 
Via Benzinga
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations
Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its  
Via Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program... 
Via Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.